Sanofi’s Lemtrada Outperforms MS Competitor, Misses Second Endpoint

Sanofi’s relapsing-remitting multiple sclerosis candidate Lemtrada achieved a 55 percent reduction in relapse rate compared with EMD Serono’s Rebif in treatment naïve patients. However, the drug missed its second primary endpoint of warding off disability and did not perform as well as it had in Phase II.
Drug Industry Daily